CLSDF continues to cover Cambridge-based Archemix; find out why (here) and (here). The aptamer company announced initiation of a Phase II study of ARC1779. The trial is designed to evaluate the safety and efficacy of ARC1779 as a first-in-class anti-platelet agent in patients suffering from a rare, life-threatening blood disorder known as thrombotic thrombocytopenic purpura [...]

• 347http://clsdf.com/2008/03/archemix-initiates-phase-ii-arc1779-study/Archemix%3A+Initiates+Phase+II+ARC1779+Study2008-03-18+20%3A34%3A00admin

CLSDF has highlighted the history and relationship of Archemix to CO in previous posts; read about it (here). It has been a very busy 2008 thus far for the Cambridge-based aptamer therapeutics company who has now (I believe it is technically a – sub – based upon University Colorado orgins…?) licensed out the right to [...]

• 329http://clsdf.com/2008/02/archemix-%e2%80%93-milestone-pandemonium/Archemix+%E2%80%93+Milestone+Pandemonium2008-02-26+15%3A39%3A00admin

You may have seen the news yesterday on the Archemix and Merck KGaA deal for the use of the SELEX® technology in the oncology field. Well Cambridge and Germany are a long way from Colorado, or are they… The origins of the Archemix/Merck deal may be traced back to the first floor of Porter Bioscience, [...]

• 182http://clsdf.com/2007/06/selecting-a-selex%c2%ae-pathway/Selecting+a+SELEX%C2%AE+Pathway2007-06-12+15%3A41%3A00admin